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Mutation in the TSC2 tumor suppressor causes
tuberous sclerosis complex, a disease charac-
terized by hamartoma formation in multiple tis-
sues. TSC2 inhibits cell growth by acting as
a GTPase-activating protein toward Rheb,
thereby inhibiting mTOR, a central controller of
cell growth. Here, we show that Wnt activates
mTOR via inhibiting GSK3 without involving b-
catenin-dependent transcription. GSK3 inhibits
the mTOR pathway by phosphorylating TSC2 in
a manner dependent on AMPK-priming phos-
phorylation. Inhibition of mTOR by rapamycin
blocks Wnt-induced cell growth and tumor de-
velopment, suggesting a potential therapeutic
value of rapamycin for cancers with activated
Wnt signaling. Our results show that, in addition
to transcriptional activation, Wnt stimulates
translation and cell growth by activating the
TSC-mTOR pathway. Furthermore, the sequen-
tial phosphorylation of TSC2 by AMPK and
GSK3 reveals a molecular mechanism of signal
integration in cell growth regulation.
INTRODUCTION
Tuberous sclerosis complex (TSC) is an autosomal-dom-
inant syndrome characterized by the development of ha-martomas in a wide range of organs and is caused by mu-
tation in either the tsc1 or the tsc2 tumor-suppressor gene
(Kwiatkowski, 2003). The TSC1 and TSC2 proteins form
a physical and functional complex in which TSC2 is the
catalytic subunit having GTPase-activating protein (GAP)
activity toward Rheb, a Ras family GTPase (Manning
and Cantley, 2003). Genetic and biochemical data indi-
cate that Rheb functions downstream of TSC2 and up-
stream of mTOR (mammalian target of rapamycin (Gao
et al., 2002; Saucedo et al., 2003; Stocker et al., 2003).
Rheb stimulates the phosphorylation of two translation
regulators, S6K (ribosomal S6 kinase 1) and 4EBP1 (eu-
karyotic initiation factor 4E binding protein 1), by activating
mTOR (Hay and Sonenberg, 2004; Manning and Cantley,
2003). Two distinct TOR complexes, TORC1 and TORC2,
have been characterized (Loewith et al., 2002; Wulls-
chleger et al., 2006). TORC1 is sensitive to rapamycin
and is responsible for phosphorylation of S6K and
4EBP1. In contrast, TORC2 is not inhibited by rapamycin.
Interestingly, TORC2 can phosphorylate and activate Akt
(Sarbassov et al., 2005), indicating a fundamental role of
mTOR in regulation of cell growth and survival.
Both TSC1 and TSC2 are phosphorylated by multiple ki-
nases, including Akt, RSK1, ERK, CDC2, MK2, and AMPK
(Astrinidis et al., 2003; Fingar and Blenis, 2004; Inoki et al.,
2003; Ma et al., 2005; Roux et al., 2004). Therefore, the
TSC1/TSC2 complex integrates signals from multiple sig-
naling pathways and influences cell growth through regu-
lation of the mTOR pathway. AMPK, a protein kinase
activated by AMP, is a cellular energy sensor and plays
an important role in cellular energy homeostasis (KahnCell 126, 955–968, September 8, 2006 ª2006 Elsevier Inc. 955
et al., 2005). We have observed that AMPK directly phos-
phorylates TSC2, and the AMPK-dependent phosphoryla-
tion of TSC2 is critical for the coordination between cell
growth and cellular energy levels (Inoki et al., 2003).
The Wnt family regulates a wide range of cellular func-
tions including cell growth, proliferation, polarity, differen-
tiation, and development (Moon et al., 2004; Wodarz and
Nusse, 1998). Furthermore, dysregulation of several com-
ponents in the Wnt pathway has been implicated in benign
colorectal adenomas and cancers (Barker and Clevers,
2000; Polakis, 2000). Activation of the canonical Wnt path-
way inhibits glycogen synthase kinase 3 (GSK3), resulting
in hypophosphorylation and thus stabilization of b-cate-
nin, which translocates into the nucleus and forms a com-
plex with the DNA binding protein T cell factor (TCF) (Cook
et al., 1996; Rubinfeld et al., 1996). The b-catenin/TCF
complex activates transcription of a wide variety of genes,
including growth-promoting genes such as cyclin D and
VEGF (Brunner et al., 1997; Easwaran et al., 2003; Mole-
naar et al., 1996; Tetsu and McCormick, 1999; Zhang
et al., 2001). Although mechanisms by which Wnt signal-
ing regulates gene transcription have been extensively
studied, little knowledge exists as to whether Wnt signal-
ing also regulates protein translation.
Here we report that TSC2 is a physiological substrate of
GSK3 and that Wnt stimulates the mTOR signaling path-
way via inhibiting GSK3 phosphorylation of TSC2. Our
studies reveal a function of TSC2/mTOR signaling in tu-
morigenesis caused by dysfunction of the Wnt pathway
and a mechanism by which Wnt stimulates protein synthe-
sis and cell growth.
RESULTS
Wnt Stimulates the mTOR Pathway In Vitro
Wnt signaling is implicated in development of cancers,
e.g., colon cancer. Since mTOR activation plays an impor-
tant role in the cell growth regulation and tumor develop-
ment, we investigated the effects of Wnt signaling on the
mTOR pathway. Phosphorylation of S6K, 4EBP1, and S6
are measured as functional assays for mTOR activity. We
found that stable expression of Wnt-1 in RIE epithelial cells
and Rat1 fibroblasts enhanced S6K phosphorylation
(T389) and decreased 4EBP1 mobility (an indicator of
phosphorylation) without significantly affecting Akt phos-
phorylation (S473) (Figure 1A). Phosphorylation of S6K
on T389, which is a direct mTOR phosphorylation site
and positively correlates with S6K kinase activity, was sen-
sitive to rapamycin, a specific inhibitor of mTOR, and wort-
mannin, a PI3K inhibitor, but was resistant to U0126,
a MEK inhibitor, which specifically inhibits ERK phosphor-
ylation (see Figure S1A in the Supplemental Data available
with this article online). Similarly, transient transfection of
Wnt-1 in HEK293T cells also stimulated S6K phosphoryla-
tion in rapamycin sensitive manner (Figure S1B). Treat-
ment of HEK293T cells with conditioned medium from
Wnt-1-expressing cells also activated phosphorylation of956 Cell 126, 955–968, September 8, 2006 ª2006 Elsevier IncmTOR substrates (Figure S1C). These results suggest
that Wnt-1 stimulates mTOR signaling.
To further verify the role of Wnt in mTOR activation, we
tested purified recombinant Wnt-3a. Both Wnt-1 and Wnt-
3a bind Frizzled receptors and LRP5/6 coreceptors and
activate the same downstream signaling branch (Pinson
et al., 2000; Tamai et al., 2000). Wnt-3a significantly in-
creased the phosphorylation of endogenous S6K on T389
(Figure 1B). Wnt-3a induced S6K phosphorylation as
quickly as did insulin (Figure 1B). Furthermore, rapamycin
and wortmannin completely blocked the Wnt-3a-induced
phosphorylation of S6K and S6, suggesting that Wnt-3a
acts through mTOR (Figure 1C). In contrast, Wnt-3a did
not affect AMPK phosphorylation on T172, which positively
correlates with AMPK activity. Moreover, the dose-depen-
dent effect of Wnt-3a on S6K phosphorylation is similar to
that of Wnt-3a on b-catenin induction (Willert et al., 2003)
(Figure S1D), indicating that activation of mTOR is likely to
be a more direct consequence of Wnt-3a stimulation.
Phosphorylation of 4EBP1 was also examined as an
additional measure for mTOR activation. Wnt-3a stimulated
4EBP1 phosphorylation, and this effect was also inhibited
by rapamycin (Figure S1E). Moreover, the increase in phos-
phorylation of S6K and 4EBP1 was faster than the induction
of b-catenin (Figure S1F). We found that Wnt-3a increased
S6K phosphorylation in mouse osteoblastic MC3T3E1
(Figure 1D), myoblastic C2C12 (Figure S1G), and epithelial
LEF cells (Figure S1H). These data show that Wnt-3a acti-
vates mTOR pathway in many different cell types.
Wnt Activates mTOR Signaling In Vivo
The above cell-based studies established that Wnt signal-
ing stimulates mTOR activity, in vitro. We further deter-
mined whether Wnt signaling activates mTOR signaling,
in vivo. Mice with either gain or loss of function of Wnt sig-
naling were used. We first examined osteoblast-specific
Wnt-10b transgenic mice, which have a high bone mass
phenotype (Figure 2A). Immunohistochemical staining
showed a significant increase of S6 phosphorylation in
mandibular bone of Wnt-10b transgenic mice (Figure 2A),
indicating that Wnt-10b activates mTOR signaling in vivo.
We next examined the Wnt coreceptor LRP6/ mice,
which display developmental defects strikingly similar to
a composite of those associated with mutations of Wnt
genes (Pinson et al., 2000). We observed that S6K phos-
phorylation in calvarial tissue was significantly decreased
in LRP6/ animals compared with the wild-type control
(Figure 2B), indicating decreased mTOR activities associ-
ated with compromised Wnt signaling.
We confirmed mTOR activation by Wnt in murine bone
marrow stromal ST2 cells (Figure 2C). Stable expression
of Wnt-10b increased phosphorylation of both S6K and
S6, and such effects were abolished by rapamycin. Fur-
thermore, we analyzed effects of Wnt signaling on cell
size, another indicator for mTOR activity. Wnt-10b expres-
sion significantly increased the size of ST2 cells (Figure 2D).
This effect was not due to an alteration in cell cycle
because Wnt-10b similarly increased the size of both G1.
Figure 1. Wnt Activates the mTOR Pathway
(A) Wnt-1 expression increases S6K phosphorylation. Phosphorylation of S6K and Akt was determined by immunoblot in RIE cells (upper panels) and
Rat1 cells (lower panels) stably transfected with empty vector or a Wnt-1 expression vector. 4EBP1 (detected by anti-4EBP1 antibody) phosphory-
lation is indicated by its electrophoretic mobility. Cells were treated with 20 nM rapamycin (Rapa.), 10 mM U0126, or 100 nM wortomannin (Wort.) for
1 hr before harvest. Quantification of relative S6K phosphorylation is indicated beneath the pS6K [T389] panels.
(B) Wnt-3a stimulates S6K phosphorylation. Serum-starved mouse embryonic fibroblasts (MEF) were treated with Wnt-3a (300 ng/ml) or insulin (400
nM) for indicated times. Phosphorylation of S6K and AKT was detected by immunoblot with phosphospecific antibodies as indicated. Quantifications
of phosphorylated S6K and AKT are indicated beneath corresponding panels.
(C) Phosphorylation of S6K and S6 in response to Wnt-3a is inhibited by rapamycin (20 nM) and wortmannin. Serum-starved MEF cells were
pretreated with inhibitors for 60 min and then stimulated with Wnt-3a (300 ng/ml) for 25 min.
(D) Wnt-3a stimulates S6K phosphorylation in osteoblastic MC3T3E1 cells.(Figure 2D) and G2 cells (data not shown). We also found
that Wnt-1 increased the size of Rat1 and RIE cells (Figures
S2A and S2B). Moreover, rapamycin partially inhibited the
Wnt effect on cell size (Figures S2A–S2C), indicating that
Wnt stimulates cell growth partially via mTOR.
Mouse mammary tumor virus (MMTV) LTR-driving ex-
pression of Wnt-1 induces mammary hyperplasia followed
by the development of mammary tumors (Li et al., 2000).
We found that mTOR activity was indeed enhanced in hy-
perplastic mammary tissues of Wnt1 mice compared with
those of the control animals (Figures 3A and 3B). To test
the functional importance of the mTOR pathway in Wnt-1-induced tumor growth, a Wnt-1-overexpressing tumor
cell line (G105), derived from a mammary tumor of an
MMTV-Wnt1 mouse,was injected intonude mice. We found
that rapamycin significantly inhibited tumor growth of
Wnt-1-expressing cells (Figures 3C and 3D and Figure S3).
These observations support the notion that the mTOR
activity is important for Wnt-1 induced tumorigenesis.
Wnt-Induced mTOR Pathway Activation Depends
on GSK3 but Not b-Catenin
To dissect mechanisms whereby Wnt stimulates mTOR
pathway, we explored the roles of several key componentsCell 126, 955–968, September 8, 2006 ª2006 Elsevier Inc. 957
Figure 2. Wnt Activates the mTOR Pathway and Increases Cell Size
(A) Transgenic expression of Wnt-10b increases S6 phosphorylation. Sections of mandibular bone from Wnt-10b transgenic or control mice were
stained with hematoxylin and eosin (H&E) and antibodies for phospho-S6 and S6 protein.
(B) LRP6 knockout decreases S6K phosphorylation. Calvarium from embryonic E19 of LRP6/ and wild-type mice (WT) were fixed and stained for
S6K phosphorylation and protein.
(C) Stable expression of Wnt-10b increases phosphorylation of S6K and S6 in ST2 cells. Rapamycin treatment inhibited phosphorylation of both S6K
and S6. The data are expressed by fold increase of relative phosphorylation (mean ± SD, n = 3, *p < 0.01).
(D) Wnt-10b increases size of ST2 cells. Control and Wnt-10b-expressing ST2 cells were analyzed by forward-scattering FACS to determine cell size.
The lower panel denotes the size of G1 cells.of the canonical pathway in regulating mTOR signaling.
DKK1 binds the Wnt coreceptor LRP5/6 and inhibits ca-
nonical Wnt signaling (Bafico et al., 2001; Mao et al.,
2001). We observed that soluble recombinant human
DKK1 protein (hDKK1) blocked Wnt-3a-induced S6K
phosphorylation in both MC3T3E1 and C2C12 cells, while
it failed to affect either basal S6K phosphorylation (Fig-
ure 4A) or insulin-induced mTOR activation (Figure S4A).
Consistent with the notion that DKK1 and Wnt-3a compete
for binding to a common target, hDKK1 showed a concen-
tration-dependent inhibition of S6K phosphorylation (Fig-
ure S4B). As a control, hDKK1 also inhibited TOPFLASH
reporter activation by Wnt-3a (Figure 4A). Taken together,
these data not only support the importance of Wnt co-
receptor LRP5/6 in mTOR signaling but also indicate that
it is specifically Wnt-3a but not another component in the
Wnt-3a preparation that stimulates mTOR pathway.958 Cell 126, 955–968, September 8, 2006 ª2006 Elsevier Inc.Dishevelled-2 (Dvl-2) acts positively in Wnt signaling
(Moon et al., 2004). Coexpression of Dvl-2 significantly ac-
tivated S6K phosphorylation but had little effect on phos-
phorylation of AMPK and GSK3 (Figure 4B). Interestingly,
the effects of Dvl-2 in enhancing S6K phosphorylation are
more prominent under glucose starvation conditions, sug-
gesting a functional interaction between the Wnt pathway
and cellular energy level (Figures 4B and 7). In addition,
coexpression of Axin1, a negative regulator in the Wnt
pathway (Zeng et al., 1997), blocked S6K phosphorylation
(Figure 4C). Furthermore, knockdown of both Axin1 and
Axin2 significantly blocked the Wnt-3a-induced S6K
phosphorylation and also slightly elevated basal S6K
phosphorylation (Figure 4C and Figure S4C). We also
tested the role of APC in Wnt-3a-induced mTOR signaling.
Wnt-3a failed to induce phosphorylation of S6 in HT29
cells that contained a truncated genomic APC mutation
Figure 3. Rapamycin Inhibits Growth of Wnt-1-Expressing Mammary Tumor Cells
(A) Wnt-1 increases phosphorylation of S6. Mammary tissues from Wnt-1-expressing (Wnt-1 TG) and control mice (WT) were analyzed by Western
blotting with anti-phospho S6 and S6 antibodies.
(B) Wnt-1 increases S6 phosphorylation as determined by immunohistochemistry staining. Mammary tissues from Wnt-1-expressing (Wnt-1 TG) or
control mice (WT) were stained for S6 phosphorylation. Rabbit IgG and Factor VIII were included as controls.
(C and D) Rapamycin inhibits growth of Wnt-1-expressing tumor cells in nude mice. Mammary gland tumor cells (cell line G105, derived from Wnt-1-
expressing tumors) were injected into nude mice. Treatment with rapamycin significantly inhibited growth of Wnt-1-expressing tumors. The data in (D)
were expressed by mean ± SE (n = 5, *p < 0.05).(Kolligs et al., 2000); however, re-expression of wild-type
APC in HT29 cells restored Wnt-3a’s capacity to stimulate
S6 phosphorylation (Figure S4D). These observations
suggest critical roles of Axin and APC in Wnt stimulation
of mTOR signaling.
GSK3 is a key component in the canonical Wnt signaling
pathway (Dominguez and Green, 2001). When a constitu-
tively active GSK3b (GSK3b-S9A) was coexpressed with
HA-S6K, it inhibited S6K phosphorylation (Figure 4E). In
contrast, knockdown of GSK3a and GSK3b by RNA inter-
ference increased S6K phosphorylation (Figure 4F). These
experiments provide compelling evidence that GSK3 in-
hibits mTOR pathway in vivo.
Activation of the mTOR pathway by Wnt-3a is rapid and,
therefore, unlikely to involve transcriptional effects of b-
catenin (Figures 1B and 1D and Figures S1F and S1G).
Consistent with this notion, coexpression of b-catenin
did not influence S6K phosphorylation (Figure 4G). We
created b-catenin-conditional knockout cells by infecting
b-catenin flox/flox MEF cells with adenovirus expressing
the Cre recombinase (Holmen et al., 2005). As expected,
Wnt-3a-stimulated phosphorylation of S6K and S6 was
similar in both the WT and b-catenin knockout MEFs
(Figure 4H). Furthermore, expression of dominant-nega-
tive TCF did not affect S6K phosphorylation (Figure 4I).Therefore, b-catenin-dependent transcription can be un-
equivocally excluded for the acute mTOR pathway activa-
tion in response to Wnt stimulation. Taken together, these
results demonstrate that the Wnt pathway bifurcates at
the level of GSK3 to regulate translation through mTOR
and transcription through b-catenin.
GSK3 and TSC2Mediate Effects of Wnt on themTOR
Pathway
The function of GSK3 in Wnt-induced mTOR activation
was further investigated. We treated HEK293 cells with
LiCl, a GSK3 inhibitor, and observed that LiCl increased
S6K phosphorylation in a dose-dependent manner (Fig-
ure 5A). In contrast, LiCl had no significant effect on Akt
phosphorylation. The inhibition of GSK3 was evident as
LiCl decreased b-catenin phosphorylation and increased
b-catenin protein (Figure S5A). LiCl was also found to stim-
ulate S6K in both MEF and LEF cells (Figure S5B). To fur-
ther support a role of GSK3, we tested a specific GSK3 in-
hibitor (GSK-I) (Barry et al., 2003). Our results showed that
GSK-I also induced S6K phosphorylation in LEF and ST2
cells (Figure S5C). Rapamycin blocked the stimulatory
effects of LiCl on the phosphorylation of S6K, S6, and
4EBP1 (Figure 5B). These observations further support
that GSK3 is a negative regulator for mTOR signaling.Cell 126, 955–968, September 8, 2006 ª2006 Elsevier Inc. 959
Figure 4. S6K Phosphorylation Is Regulated by DKK1, Dvl, Axin, and GSK3, but Not by b-Catenin
(A) DKK1 blocks the ability of Wnt-3a to stimulate S6K phosphorylation. MC3T3E1 (upper panels) and C2C12 (lower panels) cells were treated with
Wnt-3a (300 ng/ml for 30 min) in the presence or absence of recombinant human DKK1 (200 ng/ml, pretreatment for 2 hr) as indicated. In reporter
assay, MC3T3E1 cells transfected with TOPFLASH were treated with Wnt-3a in the presence or absence of hDKK1 for 18 hr (middle panel). The
data were expressed by mean ± SD (n = 3, *p < 0.01).
(B) Dvl-2 activates S6K phosphorylation. HEK293 cells were cotransfected with HA-S6K and FLAG-Dvl2 as indicated. Glucose starvation was for 2 hr.
(C) Axin is required for Wnt-induced S6K phosphorylation. LKB1-expressing HeLa cells were cotransfected with S6K and indicated combinations of
RNAi (Axin1, Axin2, and GFP as control) (Corradetti et al., 2004). Serum-starved cells were treated with Wnt-3a (300 ng/ml) for 30 min. The decreased
protein levels of Axin1 and 2 were shown.
(D) Axin inhibits S6K phosphorylation. HA-S6K was cotransfected with Axin or vector, and phosphorylation was determined.
(E) GSK3b inhibits S6K phosphorylation. HA-S6K was cotransfected with increasing amounts of GSK3b-S9A as indicated.
(F) Downregulation of GSK3 increases S6K phosphorylation. HEK293 cells were transfected with RNAi for GSK3a and GSK3b or GFP control as
indicated.
(G) S6K phosphorylation is not affected by b-catenin. HA-S6K was cotransfected with constitutive active b-catenin (CA-b-cat.) as indicated. CA-b-
catenin-activated pTOPFLASH reporter and rapamycin treatment (20 nM, for 18 hr) were indicated.960 Cell 126, 955–968, September 8, 2006 ª2006 Elsevier Inc.
We hypothesize that Wnt might activate S6K by sup-
pressing the inhibitory activity of GSK3. This hypothesis
predicts that inhibition of GSK3 should render Wnt signal-
ing ineffective in stimulating S6K phosphorylation. As
expected, treatment with either Wnt-3a or GSK-I alone in-
creased phosphorylation of S6K (Figure 5C). Interestingly,
Wnt-3a failed to further stimulate S6K phosphorylation in
the presence of GSK-I. In contrast, insulin could still stim-
ulate S6K phosphorylation even when GSK3 was inhibited
(Figure S5D). These results demonstrate that GSK3 activ-
ity is required for Wnt to stimulate S6K.
Since TSC2 is a critical upstream regulator of mTOR, we
next determined whether Wnt/GSK3 signaling functions
through TSC2. To achieve this goal, the effect of Wnt-3a
on S6K phosphorylation was examined in TSC2/ LEF
cells. We found that Wnt-3a failed to stimulate S6K phos-
phorylation in the TSC2/ LEF cells, while it activated
S6K in the wild-type TSC2+/+ LEF cells (Figure 5D). This
suggests that TSC2 is required for Wnt-3a-induced S6K
phosphorylation. However, caution has to be taken for
this interpretation because the basal S6K phosphorylation
is highly elevated in TSC2/ LEF cells. To further support
the involvement of TSC2, we tested the hierarchical rela-
tionship between GSK3 and TSC2 by using TSC2 RNA in-
terference. Downregulation of TSC2 by RNAi blocked the
inhibitory effect of GSK3b-S9A on S6K phosphorylation
(Figure 5E), indicating that TSC2 functions between
GSK3 and S6K.
Having confirmed that TSC2 is required to mediate the
GSK3 effect on S6K phosphorylation, we next determined
whether Wnt and GSK3 affect TSC2 phosphorylation.
Knockdown of endogenous GSK3a and GSK3b by RNAi
increased TSC2 mobility (Figure 5F). In addition, LiCl and
GSK-I induced a minor but reproducible increase in
TSC2 mobility (Figure S5E). Similarly, Wnt-1 also in-
creased the mobility of TSC2. Collectively, these results
suggest a role of GSK3 in TSC2 phosphorylation and sup-
port the function of endogenous GSK3 and TSC2 in S6K
regulation.
Phosphorylation of TSC2 by the Sequential Actions
of AMPK and GSK3
While searching for phosphorylation sites in TSC2, we
found that four residues, T1329, S1333, S1337, and
S1341, in TSC2 match GSK3 phosphorylation consensus
sites (Figure 6A). GSK3 recognizes serine or threonine res-
idues separated by three residues and usually requires
priming phosphorylation three residues C-terminal to the
phosphorylation site (Fiol et al., 1987). We have previously
shown that S1345 is an AMPK phosphorylation site in
TSC2 (Inoki et al., 2003). Therefore, we hypothesized that
AMPK primes TSC2 at S1345 for subsequent phosphory-
lation by GSK3 at S1341, S1337, S1333, and T1329. Whileinvestigating the relationship between AMPK and GSK3
regulation of TSC2, a report by Mak et al. showed that
TSC2 was coimmunoprecipitated with GSK3 (Mak et al.,
2003), lending additional support to our hypothesis that
TSC2 could be a direct substrate of GSK3.
We investigated whether GSK3 phosphorylates TSC2
on the predicted sites and whether this requires AMPK-
priming phosphorylation. We found that GSK3 phosphor-
ylated TSC2 only when TSC2 had been previously phos-
phorylated by AMPK (Figure 6B). Mutation of the AMPK
site S1345A in TSC2 completely eliminated GSK3 phos-
phorylation, demonstrating that AMPK-priming phosphor-
ylation was required for subsequent GSK3 phosphoryla-
tion. Analyses of additional TSC2 mutants demonstrated
that AMPK phosphorylated S1345 and GSK3 phosphory-
lated S1337 and S1341 in TSC2 in vitro (Figures S6A–
S6C). Two-dimensional phosphopeptide mapping of
both in vitro- and in vivo-phosphorylated TSC2 showed
that the peptides phosphorylated by GSK3 in vitro were in-
deed phosphorylated in vivo (Figure S6D).
If GSK3 phosphorylates TSC2 following the AMPK-
priming phosphorylation, then inhibition of GSK3 should
compromise AMPK-induced TSC2 phosphorylation. A
nonmetabolizable glucose analog, 2-deoxyglucose (2DG),
that causes cellular energy starvation, was used to acti-
vate endogenous AMPK. Indeed, we found that 2DG in-
duced an upward shift of TSC2, reflecting AMPK-induced
TSC2 phosphorylation, and, more importantly, such an
effect was significantly blocked by GSK-I (Figure S6E),
which did not directly inhibit AMPK activity (data not
shown). These data strongly suggest that AMPK and
GSK3 coordinately phosphorylate TSC2. To confirm that
GSK3 phosphorylates TSC2 on the predicted sites in
vivo, we performed two-dimensional mapping analyses
for TSC2 mutants in the presence of kinase-inactive
GSK3-KD and 2DG. Our data showed that the predicted
GSK3 sites were indeed phosphorylated in vivo, and
phosphorylation of these sites was stimulated by GSK3
and energy starvation (Figure 6C).
Antibody recognizing the GSK3 phosphorylation sites
(pS1337/pS1341) was prepared (Figure S6F). The phos-
pho-TSC2 antibody recognized overexpressed TSC2, but
not endogenous protein, possibly due to its low affinity.
Importantly, the antibody recognized TSC2, but not TSC-
2AC mutant, when GSK3 was coexpressed or cellular
energy was depleted by 2DG, indicating its specificity
(Figure S6G). We showed that phosphorylation of S1337/
1341, the direct GSK3 sites, was blocked by AMPKI, an
AMPK-specific inhibitor (Zhou et al., 2001) (Figure 6D).
Consistently, mutation of the AMPK priming site (S1345A)
prevented GSK3-induced TSC2 phosphorylation. To-
gether, these data demonstrate that both AMPK and
GSK3 phosphorylate TSC2 in a coordinated manner.(H) b-catenin is not required for Wnt-induced S6K phosphorylation. Serum-starved wild-type (b-Cat+/+) and b-catenin knockout MEF cells (b-Cat/)
were stimulated with Wnt-3a (300 ng/ml for 30 min).
(I) Dominant-negative TCF does not inhibit Wnt-induced S6K phosphorylation. Transfection of dnTCF (Flag-dnTCF), HA-Wnt1, HA-S6K, and consti-
tutively active b-catenin into HEK293 cells is indicated.Cell 126, 955–968, September 8, 2006 ª2006 Elsevier Inc. 961
Figure 5. GSK3 Mediates the Activation of mTOR by Wnt
(A) Inhibition of GSK3 by LiCl activates S6K. HEK293 cells were treated with increasing concentrations of LiCl (1, 2.5, 5, 10, and 20 mM) or NaCl
for 6 hr.
(B) Rapamycin blocks the effect of LiCl on S6K. HEK293 cells cultured in media containing LiCl or NaCl were treated with or without 20 nM rapamycin
for 30 min.
(C) Inhibition of GSK3 blocks the ability of Wnt-3a to stimulate S6K phosphorylation. Serum-starved cementoblast cells were treated with Wnt-3a
(200 ng/ml) in the presence or absence of GSK-I (20 mM).
(D) Wnt-3a stimulates S6K in wild-type but not TSC2/ LEF cells. Two exposures of S6K phosphorylation are shown. S6K is constitutively phosphor-
ylated in TSC2/ cells and could not be further activated by Wnt-3a.
(E) TSC2 knockdown blocks GSK3 inhibition of S6K. HEK293 cells were cotransfected with indicated plasmids in the presence or absence of TSC2
RNAi. TSC2 level was shown by anti-TSC2 immunoblot.
(F) GSK3 knockdown increases TSC2 mobility. HEK293 cells were transfected with RNAi for GSK3a and GSK3b as indicated (duplicated experiments
are shown). GFP denotes the GFP control RNAi. Mobility of endogenous TSC2 was determined.Functional Interdependence of AMPK and GSK3
in mTOR Regulation
Next, we addressed whether AMPK and GSK3 depend on
each other to repress mTOR pathway. First, we deter-
mined whether inhibition of S6K by GSK3 was dependent
on AMPK activity. We noticed that LiCl significantly acti-
vated S6K in old culture medium where AMPK activity
was high, while it failed to do so in fresh medium, where
AMPK activity was low (Figure 7A). Similarly, LiCl mini-
mally affected S6K phosphorylation when AMPK activity
was repressed by AMPKI (Figure 7B). Furthermore,
GSK3-S9A could not inhibit S6K phosphorylation when
AMPK was blocked by AMPKI (Figure 7C). Collectively,
we conclude that the inhibition of mTOR signaling by
GSK3 requires AMPK activity.
Reciprocally, the effects of energy starvation and AMPK
activation on the mTOR pathway also require GSK3. We
found that LiCl, without affecting AMPK phosphorylation,
largely blocked the 2DG inhibition of mTOR signaling, as962 Cell 126, 955–968, September 8, 2006 ª2006 Elsevier Incdetermined by the phosphorylation of S6K, S6, and
4EBP1 (Figure 7D). In addition, we compared 2DG effects
on mTOR in GSK3b+/+ and GSK3b/ MEF cells. 2DG
treatment caused a similar phosphorylation of AMPK in
both the GSK3b+/+ and GSK3b/ cells (Figure S7A). Im-
portantly, the 2DG-induced dephosphorylation of S6K
and 4EBP1 was partially compromised in the GSK3b/
cells. It is worth noting that GSK3a still exists in the
GSK3b/ MEF cells (Hoeflich et al., 2000) and likely con-
tributes to the cellular energy response. Nevertheless, our
data indicate a role of endogenous GSK3 in cellular energy
response. We examined the effect of AICAR, a known
AMPK activator (Corton et al., 1995), on Wnt-3a-induced
S6K phosphorylation. The relative fold of S6K inhibition
by AICAR was attenuated by Wnt-3a (Figure 7E), support-
ing a role of GSK3 in AMPK effects on mTOR signaling.
Taken together, these data support a model that GSK3
and AMPK depend on each other to regulate mTOR signal-
ing (Figure S8)..
Figure 6. Phosphorylation of TSC2 by GSK3 Requires AMPK-Priming Phosphorylation
(A) Putative GSK3 phosphorylation sites are adjacent to the AMPK phosphorylation site S1345 in rat TSC2. Predicted GSK3 phosphorylation sites are
in bold. TSC2 phosphorylation mutants used in Figures 6 and 7 are depicted.
(B) Phosphorylation by AMPK on S1345 is required for TSC2 phosphorylation by GSK3b in vitro. In vitro phosphorylation of GST-TSC2 F1 (residues
1300–1367) by HA-AMPK (immunoprecipitated from transfected HEK293 cells) was performed in the absence of 32P-ATP after HA-AMPK was
removed. GST-TSC2 F1 was then incubated with immunoprecipitated GSK3b in the presence of 32P-ATP. Phosphorylation of TSC2 by GSK3, as
indicated by an arrow, requires the priming phosphorylation by AMPK. Levels of AMPK and GSK3b were detected by anti-HA immunoblot. KD
denotes the kinase-dead mutants of AMPK or GSK3b. GST-TSC-F1 was determined by Coomassie blue staining.
(C) Phosphorylation of TSC2 on the predicted GSK3 sites in vivo. TSC2 and mutants were labeled with 32P in vivo and analyzed by two-dimensional
phosphopeptide mapping. The phosphorylation of circled spots (1–3) was enhanced by 2DG treatment (Cb) and decreased by coexpression of
GSK3b-KD (Cc). Mutation of GSK3 phosphorylation sites (2AN, 2AC, 4A) of TSC2 affected the same spots (Cd–Cf). Spot 2 contains multiple phos-
phorylated peptides as shown with higher resolution in Figure S6D.
(D) Phosphorylation of S1341/1337 in TSC2 is enhanced by GSK3 and AMPK. HEK293 cells were transfected with HA-TSC2 and HA-GSK3b as
indicated. Cells were treated with 2DG (10 mM) and AMPKI (20 mM) as indicated. Phosphorylation of TSC2 S1341/1337 was detected by the
phospho-specific antibody.GSK3 Phosphorylation of TSC2 Is Required
for mTOR Pathway Regulation by Energy
Starvation and Wnt
We proposed that phosphorylation of TSC2 by GSK3 after
the AMPK-priming phosphorylation enhances the ability
of TSC2 to inhibit mTOR signaling. To test this hypothesis,
TSC2-4A, a mutant with GSK3 sites mutated (Figure 6A),
was expressed in the TSC2/ LEF cells to produce stable
clones (Figure S7B). The basal phosphorylation of S6K and
4EBP1 of the 4A clone was higher than that of the wild-
type TSC2-expressing cells even though the TSC2-4A
was expressed slightly higher than the wild-type protein
(Figure S7B). These results suggest that phosphorylation
of TSC2 by GSK3 increases the ability of TSC2 to inhibit
mTOR signaling.
Previously, we found that mTOR activity contributed to
cell apoptosis under glucose starvation (Inoki et al., 2003).
The role of GSK3 phosphorylation of TSC2 in cellularCenergy response was investigated. We found that glucose
deprivation preferentially induced apoptosis and caused
more caspase-3 cleavage in TSC2-4A cells than in the
wild-type TSC2-expressing cells (Figures S7C and S7D).
These data demonstrate that TSC2 phosphorylation by
GSK3 is important for mTOR inhibition and, consequently,
cell viability in response to energy starvation.
The functional importance of TSC2 phosphorylation by
GSK3 in the Wnt signaling was also investigated. Wnt-3a
stimulated phosphorylation of both S6K and 4EBP1 in
the TSC2 WT but had minimal effect in the TSC2-4A-
expressing cells (Figure 7F). Thus, the GSK3 phosphoryla-
tion in TSC2 is required for Wnt-3a to stimulate phosphor-
ylation of S6K and 4EBP1.
Cyclin D1 and VEGF are important downstream targets
of both the Wnt and the mTOR pathways (Brugarolas
and Kaelin, 2004; Easwaran et al., 2003; Hashemolhos-
seini et al., 1998; Muise-Helmericks et al., 1998; Tetsuell 126, 955–968, September 8, 2006 ª2006 Elsevier Inc. 963
Figure 7. Function of GSK3 in Response to Energy Starvation and Wnt
(A) The effect of GSK3 inhibition on S6K phosphorylation depends on cellular energy status. HEK293 cells were treated with LiCl or medium change as
indicated.
(B) Activation of S6K in HEK293 cells by LiCL is impaired by an AMPK inhibitor.
(C) Inhibition of S6K by GSK3b-S9A requires AMPK activity.
(D) Inhibition of GSK3 blocks cellular response to energy depletion. HEK293 cells were treated with LiCl or NaCl (6 hr) and then washed once with
serum-free DMEM, followed by treatment with DMEM containing 2DG for 30 min. Phosphorylation of endogenous proteins was determined by im-
munoblot analyses as indicated.
(E) Wnt-3a partially blocks AICAR effect on mTOR signaling. ST2 cells were treated with or without Wnt-3a for 30 min. AICAR (2.5 mM) was added
for an additional 30 min. Phosphorylation of endogenous proteins was determined. Quantification of data from three independent experiments is
shown.
(F) Wnt-3a stimulates phosphorylation of S6K and 4EBP1 in TSC WT LEF cells but not in TSC2-4A LEF cells. TSC2/LEF cells expressing vector,
TSC2, or TSC2-4A were stimulated with Wnt-3a (300 ng/ml) for 30 min.
(G) Wnt-3a enhances cyclin D1 and VEGF expression in LEF cells expressing TSC2, but not TSC2-4A. The cells were stimulated with Wnt-3a for 6 hr.964 Cell 126, 955–968, September 8, 2006 ª2006 Elsevier Inc.
and McCormick, 1999). We observed that Wnt-3a failed
to increase protein levels of both cyclin D1 and VEGF in
TSC2/- and TSC2-4A-expressing LEF cells, whereas it
induced both proteins in wild-type TSC2-expressing cells
(Figure 7G). To further test the role of mTOR in Wnt signal-
ing, we determined the effects of rapamycin on cyclin D1
induction by Wnt-3a. We found that rapamycin almost
completely blocked the Wnt-3a-induced accumulation of
cyclin D1 (Figure 7H). Quantitative RT-PCR analysis indi-
cated that Wnt-3a had little effect on cyclin D1 mRNA
level, suggesting that Wnt-3a mainly stimulated cyclin
D1 translation. These data are consistent with the obser-
vation that Wnt-3a fails to induce cyclin D1 in TSC2-4A-
expressing cells (Figure 7G) but contradicts a prevailing
model that Wnt induces cyclin D1 mRNA. It is worth noting
that recent reports (Sansom et al., 2005; van de Wetering
et al., 2002) disputed the model of cyclin D1 mRNA induc-
tion by Wnt. Our results support the functional importance
of the TSC2/mTOR pathway in Wnt signaling and have
revealed that a branch of Wnt signaling is to stimulate
translation and cell growth via the TSC-mTOR pathway.
DISCUSSION
mTOR signaling is implicated in receiving signals from mi-
togenic growth factors, nutrients, cellular energy levels,
and stress conditions to stimulate protein synthesis and
cell growth (Fingar and Blenis, 2004; Hay and Sonenberg,
2004; Wullschleger et al., 2006). However, the molecular
mechanism of how multiple signaling pathways integrate
in the cell to produce a concerted physiological response
is unknown. In this report, we demonstrate that TSC2
functions as a key integration point to coordinate cell
growth signals with cellular energy status. Furthermore,
our results indicate a critical role of mTOR signaling in me-
diating Wnt effects on cell growth and tumor development.
Regulation of the mTOR Pathway by Wnt
Activation of the canonical Wnt signaling results in accu-
mulation of b-catenin and transcription activation. We
present data that Wnt also regulates translation by stimu-
lating the mTOR pathway, as determined by the increase
in phosphorylation of S6K, S6, and 4EBP1. Both in vitro
and in vivo data support Wnt regulation of mTOR signaling.
The acute stimulation of mTOR signaling by Wnt is inde-
pendent of b-catenin-dependent transcription. In contrast,
Dvl, Axin, APC, and GSK3 are involved in mTOR pathway
regulation. We propose that Wnt signaling regulates both
transcription via b-catenin and translation via mTOR
through two different signaling branches downstream of
GSK3 (Figure S8).
GSK3 is required for Wnt regulation of mTOR signaling.
Interestingly, Mak et al. reported that TSC2 can be coim-
munoprecipitated with GSK3, Axin, and Dvl (Mak et al.,2003). Furthermore, Wnt treatment decreases the associ-
ation between TSC2 and GSK3 or Axin but stimulates
the interaction between TSC2 and Dvl (Mak et al., 2005).
These observations lend additional support to our hy-
pothesis that Wnt inhibits the GSK3-dependent phos-
phorylation of TSC2, although Mak et al. mainly addressed
the effects of TSC-mTOR signaling on the Wnt pathway
(Mak et al., 2003).
Activation of mTOR signaling increases protein synthe-
sis and promotes cell growth. Our data demonstrate that
mTOR signaling may play a critical role in mediating
growth-stimulatory and tumorigenic effects of Wnt signal-
ing. Wnt-3a fails to induce cyclin D protein expression in
the presence of rapamycin, and growth of the Wnt-1-
expressing tumor cells is strongly inhibited by rapamycin.
This functional connection between Wnt and mTOR
suggests a therapeutic potential of rapamycin in treating
diseases caused by the dysregulation of Wnt signaling
pathway, such as colorectal cancer.
Integration of Signaling Pathways at TSC2
by Coordinated Phosphorylation
Cells are simultaneously exposed to a wide range of extra-
cellular and intracellular signals, including mitogenic
growth factors, cellular energy levels, nutrient availability,
and various stress conditions. All these signals influence
cell growth; therefore, cells must integrate these inputs
to produce a concerted response. A basic question in
cell biology is how these multiple signals are integrated
at the molecular level.
Low cellular energy level activates AMPK, which then
phosphorylates multiple cellular metabolic targets to
maintain intracellular ATP homeostasis (Kahn et al.,
2005). AMPK inhibits protein synthesis, one of the most
energy-consuming cellular activities, by inhibiting both
translation initiation and elongation (Bolster et al., 2002;
Horman et al., 2002). Previously we found that AMPK
phosphorylation of TSC2 is required to inhibit mTOR path-
way (Inoki et al., 2003). Here, we have discovered that
phosphorylation of TSC2 by AMPK provides the prim-
ing phosphorylation for subsequent phosphorylation by
GSK3. We propose that AMPK and GSK3 coordinately
phosphorylate TSC2 and depend on each other to repress
mTOR signaling (Figure S8). When GSK3 is inhibited, the
AMPK inhibition on S6K phosphorylation is significantly
reduced (Figures 7D and 7E). Reciprocally, when AMPK
activity is affected, the effect of GSK3 on S6K phosphor-
ylation also changes accordingly. For instance, when
AMPK is inhibited by AMPKI, the GSK3 repression of
mTOR signaling is significantly decreased (Figure 7C). In
contrast, when AMPK is activated by AICAR, Wnt-3a stim-
ulated S6K phosphorylation by a greater relative fold of
induction (Figure 7E). Similarly, Dvl-2’s stimulatory effect
on S6K phosphorylation was amplified under glucose(H) Rapamycin blocks Wnt-3a-induced accumulation of cyclin D1. MEF cells were exposed to Wnt-3a with or without rapamycin for 6 hr. The cyclin D1
protein level was determined by immunoblot analysis. Quantification was performed on four independent experiments (mean ± SD, *p < 0.01 versus
other groups). Cyclin D1 mRNA level was determined by quantitative RT-PCR.Cell 126, 955–968, September 8, 2006 ª2006 Elsevier Inc. 965
starvation conditions (Figure 4B). Therefore, our studies
demonstrating the coordinated phosphorylation of TSC2
by AMPK and GSK3 provide a clear mechanism to explain
how different signaling pathways are integrated at a
molecular level.
It is worth noting that TSC2 is also phosphorylated by
other kinases, including Akt, MK2, CDK, ERK, and RSK1.
How these multiple phosphorylation events are integrated
by TSC2 to regulate cell growth is an exciting topic and re-
quires future studies. A database search of the human pro-
teome for sequences with GSK3 sites followed by an
AMPK consensus site revealed many proteins with such
a motif. We speculate that the combinatory phosphoryla-
tion by AMPK and GSK3 could be a mechanism widely
used for regulation of cellular activities. This notion is
consistent with the fact that both AMPK and GSK3 are in-
volved in regulation of a wide range of cellular processes.
EXPERIMENTAL PROCEDURES
Materials and other experimental procedures are described in the
Supplemental Data.
Cell Culture, Transfection, and Retroviral Infection
HEK293 cells, 293T cells, Rat1 cells, RIE cells, bone marrow stromal
(ST2) cells, cementoblast cells, MC3T3E1 cells, and MEF cells were
cultured in DMEM (Invitrogen) containing 10% fetal bovine serum (In-
vitrogen) and 50 mg/mL penicillin/streptomycin (P/S). Mouse cemento-
blasts were isolated as described previously (Ouyang et al., 2000).
TSC2/ LExF2 cells (LEF) were maintained in DMEM/F12 (Invitrogen)
containing 10% FBS and 50 mg/mL P/S (Inoki et al., 2003). HT29
cell lines were cultured in McCoy’s 5A supplemented with 10% FBS,
100 units/ml penicillin, 100 mg/ml streptomycin, 0.6 mg/ml hygromy-
cin, and 100 mM ZnCl to induce APC (Kolligs et al., 2000). MEF cells
(GSK3-b/, GSK3-b+/+) were prepared from a single embryonic day
14.5 litter, and early passages were used. Transfection with lipofect-
amine (Invitrogen) was performed according to the manufacturer’s
instructions.
To generate mutant TSC-expressing cells, retroviral infection was
performed by transfecting 293 Phoenix retrovirus packaging cells
with empty vector, pPGS-CITE-neo-TSC2-4A, or pPGS-CITE-neo-
WT-TSC2 (Tang et al., 2003). Forty-eight hours posttransfection, retro-
viral supernatants were supplemented with 5 mg/mL polybrene, filtered
through a 0.45 mm filter, and used for infection of LEF (TSC2/) cells.
Immunoprecipitation and Kinase Assay
For the AMPK kinase assays, HEK293 cells were transfected with
AMPKaI. Transfected HEK 293 cells were treated with 50 mM 2-DG
for 30 min and then lysed in lysis buffer A (50 mM Tris-HCl [pH 7.5],
50 mM NaF, 5 mM pyrophosphate, 1 mM EDTA, 1 mM DTT, 10% glyc-
erol, 1% Triton X-100, 1 mM PMSF, 10 mg/ml leupeptin, and 10 mg/ml
aprotinin) and immunoprecipitated by HA antibody. The immunopre-
cipitates were washed twice with buffer A and then washed twice
with buffer B (50 mM HEPES [pH 7.5], 1 mM EDTA, 1 mM DTT, 10%
glycerol), once with buffer N, and once with HEPES buffer (25 mM
HEPES [pH 8], 0.5 mM EDTA, 0.025% b-mercaptoethanol). Immuno-
precipitated AMPK was subjected to a kinase reaction mixtures
(18 mM HEPES [pH 7.5], 10 mM magnesium acetate, 50 mM cold
ATP, 1 mM DTT, 1 mCi [g-32P]ATP) with purified bacterial-derived TSC2
fragments as substrates. Reaction mixtures were then incubated for
30 min at 30C, terminated with SDS sample buffer, and subjected
to SDS-PAGE and autoradiography.
For the GSK3 kinase assay, HEK 293 cells transfected with HA-
GSK3b plasmids were harvested with RIPA buffer (50 mM Tris-HCl966 Cell 126, 955–968, September 8, 2006 ª2006 Elsevier Inc.[pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaF,
0.5% deoxycholic acid, 0.1% SDS, 1% Triton X-100, 1 mM DTT,
1mM PMSF, 10 mg/ml leupeptin, and 10 mg/ml aprotinin) and were im-
munoprecipitated by HA. The immunoprecipitates were washed four
times with RIPA buffer and once with HEPES buffer and then subjected
to kinase reaction by using the AMPK phosphorylated or unphos-
phorylated TSC2 fragments as substrates. The condition of the kinase
reaction was same as AMPK kinase assay.
Supplemental Data
Supplemental Data include eight figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://
www.cell.com/cgi/content/full/126/5/955/DC1/.
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